u 92032 has been researched along with Seizures in 1 studies
*Seizures: Clinical or subclinical disturbances of cortical function due to a sudden, abnormal, excessive, and disorganized discharge of brain cells. Clinical manifestations include abnormal motor, sensory and psychic phenomena. Recurrent seizures are usually referred to as EPILEPSY or seizure disorder. [MeSH]
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Annoura, H; Imajo, S; Miyajima, A; Nakanishi, K; Takemoto, N; Tamura, S; Tamura-Horikawa, Y; Toba, T | 1 |
1 other study(ies) available for u 92032 and Seizures
| Article | Year |
|---|---|
Discovery of (2S)-1-(4-amino-2,3,5- trimethylphenoxy)-3-[4-[4-(4- fluorobenzyl)phenyl]-1-piperazinyl]-2-propanol dimethanesulfonate (SUN N8075): a dual Na(+) and Ca(2+) channel blocker with antioxidant activity.
Topics: Acoustic Stimulation; Aniline Compounds; Animals; Anticonvulsants; Antioxidants; Calcium Channel Blockers; Cerebral Cortex; In Vitro Techniques; Lipid Peroxidation; Mice; Mice, Inbred DBA; Models, Molecular; Molecular Conformation; Neuroprotective Agents; Piperazines; Rats; Seizures; Sodium Channel Blockers | 2000 |